ID,Description,GeneRatio,BgRatio,RichFactor,FoldEnrichment,zScore,pvalue,p.adjust,qvalue,geneID,Count
R-HSA-6783783,Interleukin-10 signaling,9/75,29/3769,0.3103448275862069,15.595862068965516,11.241663510111994,2.1831808809059386e-9,8.077769259351973e-7,6.710408602363517e-7,CXCL2/TIMP1/CSF3/CCL2/IL1R1/IL1B/LIF/IL6/FPR1,9
R-HSA-1280215,Cytokine Signaling in Immune system,23/75,309/3769,0.0744336569579288,3.7405393743257824,7.163328531353335,1.0850263525629673e-8,2.0072987522414895e-6,1.6675141839388763e-6,IL4R/CXCL2/TIMP1/CSF3/CCL2/CISH/IL1R1/CDKN1A/IRF1/IL1B/LIF/IL6/IFITM3/OSMR/GBP2/IL7R/FPR1/ANXA2/SOCS3/IFITM2/IFITM1/HLA-DRB5/CEBPD,23
R-HSA-449147,Signaling by Interleukins,17/75,200/3769,0.085,4.271533333333333,6.77377406141373,2.0656505511105148e-7,2.547635679702968e-5,2.1163858278044573e-5,IL4R/CXCL2/TIMP1/CSF3/CCL2/CISH/IL1R1/CDKN1A/IL1B/LIF/IL6/OSMR/IL7R/FPR1/ANXA2/SOCS3/CEBPD,17
R-HSA-168256,Immune System,33/75,759/3769,0.043478260869565216,2.1849275362318843,5.20435682590266,1.9134409834710578e-6,1.6784502190968952e-4,1.3943313342142062e-4,PLAUR/SLC11A1/IL4R/CXCL2/TIMP1/CRISPLD2/CSF3/CCL2/CLEC2B/CISH/IL1R1/CDKN1A/IRF1/IL1B/CD93/RAC2/LIF/PTPN22/IL6/IFITM3/OSMR/GBP2/IL7R/FPR2/FPR1/ANXA2/SOCS3/IFITM2/IFITM1/SERPINA3/CASP4/HLA-DRB5/CEBPD,33
R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,9/75,61/3769,0.14754098360655737,7.414426229508196,7.195989198452134,2.268175971752561e-6,1.6784502190968952e-4,1.3943313342142062e-4,IL4R/TIMP1/CCL2/CDKN1A/IL1B/LIF/IL6/SOCS3/CEBPD,9
R-HSA-909733,Interferon alpha/beta signaling,6/75,26/3769,0.23076923076923078,11.596923076923078,7.724923289039652,8.518876140174442e-6,5.04134612120542e-4,4.187974587174916e-4,IRF1/IFITM3/GBP2/SOCS3/IFITM2/IFITM1,6
R-HSA-6783589,Interleukin-6 family signaling,4/75,8/3769,0.5,25.126666666666665,9.732586763740537,9.537681850929173e-6,5.04134612120542e-4,4.187974587174916e-4,LIF/IL6/OSMR/SOCS3,4
R-HSA-109582,Hemostasis,18/75,296/3769,0.060810810810810814,3.0559459459459464,5.249800371433195,1.1960718453720603e-5,5.531832284845779e-4,4.595433932218969e-4,TFPI/SELE/PLAUR/TIMP1/VWF/TNFRSF10B/SRGN/CDK2/IRF1/RAC2/THBS1/SLC16A3/TNFRSF10D/THBD/ANXA2/MAFF/SERPINA3/ITGB3,18
R-HSA-5218859,Regulated Necrosis,5/75,24/3769,0.20833333333333334,10.469444444444445,6.630432276334214,8.630765106530852e-5,0.003548203432684906,0.002947582936967262,TNFRSF10B/IRF1/IL1B/MLKL/CASP4,5
R-HSA-5620971,Pyroptosis,3/75,11/3769,0.2727272727272727,13.705454545454543,6.01237132332334,0.0011135864560586231,0.04120269887416905,0.03422813107043348,IRF1/IL1B/CASP4,3
R-HSA-114608,Platelet degranulation,6/75,62/3769,0.0967741935483871,4.863225806451613,4.3699078451120466,0.0012895252839713403,0.043374941369945075,0.0360326682219743,TIMP1/VWF/SRGN/THBS1/SERPINA3/ITGB3,6
R-HSA-76005,Response to elevated platelet cytosolic Ca2+,6/75,64/3769,0.09375,4.71125,4.266322923244055,0.0015240410836855661,0.04699126674697162,0.039036841792647846,TIMP1/VWF/SRGN/THBS1/SERPINA3/ITGB3,6
R-HSA-913531,Interferon Signaling,7/75,92/3769,0.07608695652173914,3.8236231884057976,3.90653276987695,0.0021094985674268967,0.0600395746113809,0.04987640337559951,IRF1/IFITM3/GBP2/SOCS3/IFITM2/IFITM1/HLA-DRB5,7
R-HSA-202733,Cell surface interactions at the vascular wall,6/75,74/3769,0.08108108108108109,4.074594594594595,3.8056963263681394,0.003218604498487652,0.0695361010648166,0.05776540970391592,SELE/TNFRSF10B/SLC16A3/TNFRSF10D/THBD/ITGB3,6
R-HSA-202427,Phosphorylation of CD3 and TCR zeta chains,2/75,5/3769,0.4,20.101333333333336,6.089217844683607,0.003758708165665762,0.0695361010648166,0.05776540970391592,PTPN22/HLA-DRB5,2
R-HSA-354194,GRB2:SOS provides linkage to MAPK signaling for Integrins,2/75,5/3769,0.4,20.101333333333336,6.089217844683607,0.003758708165665762,0.0695361010648166,0.05776540970391592,VWF/ITGB3,2
R-HSA-444473,Formyl peptide receptors bind formyl peptides and many other ligands,2/75,5/3769,0.4,20.101333333333336,6.089217844683607,0.003758708165665762,0.0695361010648166,0.05776540970391592,FPR2/FPR1,2
R-HSA-75205,Dissolution of Fibrin Clot,2/75,5/3769,0.4,20.101333333333336,6.089217844683607,0.003758708165665762,0.0695361010648166,0.05776540970391592,PLAUR/ANXA2,2
R-HSA-9675126,Diseases of mitotic cell cycle,2/75,5/3769,0.4,20.101333333333336,6.089217844683607,0.003758708165665762,0.0695361010648166,0.05776540970391592,CDK2/CDKN1A,2
R-HSA-9687139,Aberrant regulation of mitotic cell cycle due to RB1 defects,2/75,5/3769,0.4,20.101333333333336,6.089217844683607,0.003758708165665762,0.0695361010648166,0.05776540970391592,CDK2/CDKN1A,2
R-HSA-140877,Formation of Fibrin Clot (Clotting Cascade),3/75,17/3769,0.17647058823529413,8.868235294117648,4.632420957737609,0.004211381440216047,0.07420053013713988,0.06164026970140781,TFPI/VWF/THBD,3
R-HSA-187577,SCF(Skp2)-mediated degradation of p27/p21,2/75,6/3769,0.3333333333333333,16.75111111111111,5.501198860240235,0.005565538449353041,0.08236996905042501,0.06842683061941425,CDK2/CDKN1A,2
R-HSA-372708,p130Cas linkage to MAPK signaling for integrins,2/75,6/3769,0.3333333333333333,16.75111111111111,5.501198860240235,0.005565538449353041,0.08236996905042501,0.06842683061941425,VWF/ITGB3,2
R-HSA-5661231,Metallothioneins bind metals,2/75,6/3769,0.3333333333333333,16.75111111111111,5.501198860240235,0.005565538449353041,0.08236996905042501,0.06842683061941425,MT1X/MT1A,2
R-HSA-6788467,IL-6-type cytokine receptor ligand interactions,2/75,6/3769,0.3333333333333333,16.75111111111111,5.501198860240235,0.005565538449353041,0.08236996905042501,0.06842683061941425,LIF/OSMR,2
R-HSA-877300,Interferon gamma signaling,4/75,40/3769,0.1,5.025333333333334,3.6464753896305773,0.007688662875358777,0.09180383960978854,0.07626378710116147,IRF1/GBP2/SOCS3/HLA-DRB5,4
R-HSA-5660526,Response to metal ions,2/75,7/3769,0.2857142857142857,14.358095238095238,5.039898534208548,0.007691673048387688,0.09180383960978854,0.07626378710116147,MT1X/MT1A,2
R-HSA-69563,p53-Dependent G1 DNA Damage Response,2/75,7/3769,0.2857142857142857,14.358095238095238,5.039898534208548,0.007691673048387688,0.09180383960978854,0.07626378710116147,CDK2/CDKN1A,2
R-HSA-69580,p53-Dependent G1/S DNA damage checkpoint,2/75,7/3769,0.2857142857142857,14.358095238095238,5.039898534208548,0.007691673048387688,0.09180383960978854,0.07626378710116147,CDK2/CDKN1A,2
R-HSA-75158,TRAIL  signaling,2/75,7/3769,0.2857142857142857,14.358095238095238,5.039898534208548,0.007691673048387688,0.09180383960978854,0.07626378710116147,TNFRSF10B/TNFRSF10D,2
R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,2/75,7/3769,0.2857142857142857,14.358095238095238,5.039898534208548,0.007691673048387688,0.09180383960978854,0.07626378710116147,CSF3/SOCS3,2
R-HSA-380108,Chemokine receptors bind chemokines,3/75,22/3769,0.13636363636363635,6.852727272727272,3.9225222365831236,0.008881238309340976,0.1012403055994498,0.08410289967294265,CXCL2/CCL2/CXCL11,3
R-HSA-5083635,Defective B3GALTL causes PpS,3/75,23/3769,0.13043478260869565,6.5547826086956515,3.8070162607843416,0.010069188198015281,0.1012403055994498,0.08410289967294265,THBS1/ADAMTS1/ADAMTS9,3
R-HSA-5173214,O-glycosylation of TSR domain-containing proteins,3/75,23/3769,0.13043478260869565,6.5547826086956515,3.8070162607843416,0.010069188198015281,0.1012403055994498,0.08410289967294265,THBS1/ADAMTS1/ADAMTS9,3
R-HSA-6803211,TP53 Regulates Transcription of Death Receptors and Ligands,2/75,8/3769,0.25,12.563333333333333,4.664595673309743,0.01012403055994498,0.1012403055994498,0.08410289967294265,TNFRSF10B/TNFRSF10D,2
R-HSA-69615,G1/S DNA Damage Checkpoints,2/75,8/3769,0.25,12.563333333333333,4.664595673309743,0.01012403055994498,0.1012403055994498,0.08410289967294265,CDK2/CDKN1A,2
R-HSA-982772,Growth hormone receptor signaling,2/75,8/3769,0.25,12.563333333333333,4.664595673309743,0.01012403055994498,0.1012403055994498,0.08410289967294265,CISH/SOCS3,2
R-HSA-9860931,Response of endothelial cells to shear stress,4/75,44/3769,0.09090909090909091,4.568484848484848,3.392225308781215,0.010758604156839232,0.10475482994817147,0.08702250453731458,ADM/CDH5/ANXA2/ITGB3,4
R-HSA-5357801,Programmed Cell Death,5/75,69/3769,0.07246376811594203,3.641545893719807,3.1551461203004387,0.011387689064111972,0.10536146777736723,0.08752645402842457,TNFRSF10B/IRF1/IL1B/MLKL/CASP4,5
R-HSA-76002,"Platelet activation, signaling and aggregation",7/75,125/3769,0.056,2.8141866666666666,2.9389041784185905,0.011390428948904565,0.10536146777736723,0.08752645402842457,TIMP1/VWF/SRGN/RAC2/THBS1/SERPINA3/ITGB3,7
R-HSA-425410,Metal ion SLC transporters,2/75,9/3769,0.2222222222222222,11.167407407407408,4.350860826834087,0.012849911823324267,0.11056900871232507,0.09185249087908658,SLC11A1/CP,2
R-HSA-6791312,TP53 Regulates Transcription of Cell Cycle Genes,2/75,9/3769,0.2222222222222222,11.167407407407408,4.350860826834087,0.012849911823324267,0.11056900871232507,0.09185249087908658,CDK2/CDKN1A,2
R-HSA-9674555,Signaling by CSF3 (G-CSF),2/75,9/3769,0.2222222222222222,11.167407407407408,4.350860826834087,0.012849911823324267,0.11056900871232507,0.09185249087908658,CSF3/SOCS3,2
R-HSA-418990,Adherens junctions interactions,3/75,27/3769,0.1111111111111111,5.583703703703704,3.405525685682451,0.01571257051436581,0.12754535606142614,0.10595517487890879,FOXF1/ANGPTL4/CDH5,3
R-HSA-354192,Integrin signaling,2/75,10/3769,0.2,10.050666666666668,4.0830250143227556,0.01585699021304217,0.12754535606142614,0.10595517487890879,VWF/ITGB3,2
R-HSA-9825892,Regulation of MITF-M-dependent genes involved in cell cycle and proliferation,2/75,10/3769,0.2,10.050666666666668,4.0830250143227556,0.01585699021304217,0.12754535606142614,0.10595517487890879,CDK2/CDKN1A,2
R-HSA-375276,Peptide ligand-binding receptors,6/75,105/3769,0.05714285714285714,2.8716190476190477,2.771226393520517,0.01722434671500446,0.13559592094790746,0.11264298411604262,EDN1/CXCL2/CCL2/CXCL11/FPR2/FPR1,6
R-HSA-9855142,Cellular responses to mechanical stimuli,4/75,52/3769,0.07692307692307693,3.8656410256410263,2.9645911687668507,0.019047290393997093,0.14158643597688514,0.11761945748293161,ADM/CDH5/ANXA2/ITGB3,4
R-HSA-6802948,Signaling by high-kinase activity BRAF mutants,2/75,11/3769,0.18181818181818182,9.136969696969697,3.850510274133713,0.01913330215903853,0.14158643597688514,0.11761945748293161,VWF/ITGB3,2
R-HSA-9860927,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",2/75,11/3769,0.18181818181818182,9.136969696969697,3.850510274133713,0.01913330215903853,0.14158643597688514,0.11761945748293161,ANXA2/ITGB3,2
R-HSA-69231,Cyclin D associated events in G1,2/75,12/3769,0.16666666666666666,8.375555555555556,3.6458802273775386,0.02266723788897364,0.15824298148906127,0.1314564739539286,CDK2/CDKN1A,2
R-HSA-69236,G1 Phase,2/75,12/3769,0.16666666666666666,8.375555555555556,3.6458802273775386,0.02266723788897364,0.15824298148906127,0.1314564739539286,CDK2/CDKN1A,2
R-HSA-9759475,Regulation of CDH11 Expression and Function,2/75,12/3769,0.16666666666666666,8.375555555555556,3.6458802273775386,0.02266723788897364,0.15824298148906127,0.1314564739539286,FOXF1/ANGPTL4,2
R-HSA-373076,Class A/1 (Rhodopsin-like receptors),8/75,179/3769,0.0446927374301676,2.245959031657356,2.433440248719303,0.024539224997109647,0.16813913423945498,0.13967746002253445,EDN1/CXCL2/CCL2/CXCL11/FPR2/FPR1/GPR4/S1PR3,8
R-HSA-5213460,RIPK1-mediated regulated necrosis,2/75,13/3769,0.15384615384615385,7.731282051282053,3.4637321931986884,0.02644753238770262,0.17167696462192927,0.14261642580257,TNFRSF10B/MLKL,2
R-HSA-5674135,MAP2K and MAPK activation,2/75,13/3769,0.15384615384615385,7.731282051282053,3.4637321931986884,0.02644753238770262,0.17167696462192927,0.14261642580257,VWF/ITGB3,2
R-HSA-5675482,Regulation of necroptotic cell death,2/75,13/3769,0.15384615384615385,7.731282051282053,3.4637321931986884,0.02644753238770262,0.17167696462192927,0.14261642580257,TNFRSF10B/MLKL,2
R-HSA-216083,Integrin cell surface interactions,4/75,59/3769,0.06779661016949153,3.4070056497175143,2.654934394953556,0.02886590296968349,0.1813526321191339,0.1506542491572891,VWF/THBS1/COL4A1/ITGB3,4
R-HSA-3906995,Diseases associated with O-glycosylation of proteins,3/75,34/3769,0.08823529411764706,4.434117647058824,2.8658071239024703,0.029118969307417454,0.1813526321191339,0.1506542491572891,THBS1/ADAMTS1/ADAMTS9,3
R-HSA-69202,Cyclin E associated events during G1/S transition,2/75,14/3769,0.14285714285714285,7.179047619047619,3.3000325418447223,0.030463256569115547,0.1813526321191339,0.1506542491572891,CDK2/CDKN1A,2
R-HSA-9759476,Regulation of Homotypic Cell-Cell Adhesion,2/75,14/3769,0.14285714285714285,7.179047619047619,3.3000325418447223,0.030463256569115547,0.1813526321191339,0.1506542491572891,FOXF1/ANGPTL4,2
R-HSA-9764260,Regulation of Expression and Function of Type II Classical Cadherins,2/75,14/3769,0.14285714285714285,7.179047619047619,3.3000325418447223,0.030463256569115547,0.1813526321191339,0.1506542491572891,FOXF1/ANGPTL4,2
R-HSA-6798695,Neutrophil degranulation,8/75,187/3769,0.0427807486631016,2.149875222816399,2.2979806199371176,0.030878961685149833,0.1813526321191339,0.1506542491572891,PLAUR/SLC11A1/CRISPLD2/CD93/FPR2/FPR1/ANXA2/SERPINA3,8
R-HSA-1266695,Interleukin-7 signaling,2/75,15/3769,0.13333333333333333,6.700444444444444,3.1516998138099654,0.03470380865563553,0.20063139379039288,0.16666960735930222,CISH/IL7R,2
R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),3/75,38/3769,0.07894736842105263,3.9673684210526314,2.619318302438658,0.03880677988426774,0.20123326571504419,0.16716959769215622,CDK2/CDKN1A/IL6,3
R-HSA-425366,"Transport of bile salts and organic acids, metal ions and amine compounds",3/75,38/3769,0.07894736842105263,3.9673684210526314,2.619318302438658,0.03880677988426774,0.20123326571504419,0.16716959769215622,SLC11A1/CP/SLC16A3,3
R-HSA-6802946,Signaling by moderate kinase activity BRAF mutants,2/75,16/3769,0.125,6.281666666666666,3.016333316933401,0.039158905760765354,0.20123326571504419,0.16716959769215622,VWF/ITGB3,2
R-HSA-6802949,Signaling by RAS mutants,2/75,16/3769,0.125,6.281666666666666,3.016333316933401,0.039158905760765354,0.20123326571504419,0.16716959769215622,VWF/ITGB3,2
R-HSA-6802955,Paradoxical activation of RAF signaling by kinase inactive BRAF,2/75,16/3769,0.125,6.281666666666666,3.016333316933401,0.039158905760765354,0.20123326571504419,0.16716959769215622,VWF/ITGB3,2
R-HSA-69656,Cyclin A:Cdk2-associated events at S phase entry,2/75,16/3769,0.125,6.281666666666666,3.016333316933401,0.039158905760765354,0.20123326571504419,0.16716959769215622,CDK2/CDKN1A,2
R-HSA-9649948,Signaling downstream of RAS mutants,2/75,16/3769,0.125,6.281666666666666,3.016333316933401,0.039158905760765354,0.20123326571504419,0.16716959769215622,VWF/ITGB3,2
R-HSA-9656223,Signaling by RAF1 mutants,2/75,16/3769,0.125,6.281666666666666,3.016333316933401,0.039158905760765354,0.20123326571504419,0.16716959769215622,VWF/ITGB3,2
R-HSA-76009,Platelet Aggregation (Plug Formation),2/75,17/3769,0.11764705882352941,5.912156862745098,2.892030747439259,0.043818575670171965,0.22209415065703597,0.18449926597967145,VWF/ITGB3,2
R-HSA-8953897,Cellular responses to stimuli,10/75,276/3769,0.036231884057971016,1.8207729468599034,2.0179756190202935,0.04488370586738522,0.2244185293369261,0.18643018653309368,CCL2/CDK2/CDKN1A/IL6/ADM/CDH5/ANXA2/MT1X/MT1A/ITGB3,10
R-HSA-1474244,Extracellular matrix organization,7/75,167/3769,0.041916167664670656,2.106427145708583,2.083755873533812,0.046693343832164086,0.22593771992706116,0.18769221683841214,TIMP1/VWF/THBS1/ADAMTS1/ADAMTS9/COL4A1/ITGB3,7
R-HSA-500792,GPCR ligand binding,9/75,240/3769,0.0375,1.8845,2.017507984324073,0.04675749704620839,0.22593771992706116,0.18769221683841214,EDN1/CXCL2/CCL2/ADM/CXCL11/FPR2/FPR1/GPR4/S1PR3,9
R-HSA-421270,Cell-cell junction organization,3/75,41/3769,0.07317073170731707,3.677073170731707,2.4555673564237552,0.04701947144428029,0.22593771992706116,0.18769221683841214,FOXF1/ANGPTL4/CDH5,3
R-HSA-3000170,Syndecan interactions,2/75,18/3769,0.1111111111111111,5.583703703703704,2.77726224471288,0.04867314881689395,0.2308854495160354,0.19180242178857002,THBS1/ITGB3,2
R-HSA-202403,TCR signaling,2/75,19/3769,0.10526315789473684,5.289824561403508,2.6707813275999537,0.05371325044635093,0.24918894496316804,0.2070076015056759,PTPN22/HLA-DRB5,2
R-HSA-1474228,Degradation of the extracellular matrix,4/75,72/3769,0.05555555555555555,2.791851851851852,2.187163531951348,0.05387869080284714,0.24918894496316804,0.2070076015056759,TIMP1/ADAMTS1/ADAMTS9/COL4A1,4
R-HSA-3000171,Non-integrin membrane-ECM interactions,3/75,48/3769,0.0625,3.140833333333333,2.1267247002841185,0.06919655867402241,0.3160830457949172,0.2625782343445685,THBS1/COL4A1/ITGB3,3
R-HSA-5633008,TP53 Regulates Transcription of Cell Death Genes,2/75,23/3769,0.08695652173913043,4.369855072463769,2.309558080143955,0.07555134181364205,0.33593972592780774,0.2790736841277948,TNFRSF10B/TNFRSF10D,2
R-HSA-194138,Signaling by VEGF,3/75,50/3769,0.06,3.0151999999999997,2.043749673778826,0.07626739723766446,0.33593972592780774,0.2790736841277948,FLT1/CDH5/ITGB3,3
R-HSA-8951664,Neddylation,3/75,50/3769,0.06,3.0151999999999997,2.043749673778826,0.07626739723766446,0.33593972592780774,0.2790736841277948,CISH/CDKN1A/SOCS3,3
R-HSA-5173105,O-linked glycosylation,3/75,51/3769,0.058823529411764705,2.956078431372549,2.0037996338308055,0.07991878329500272,0.33835567749519396,0.2810806766105167,THBS1/ADAMTS1/ADAMTS9,3
R-HSA-1222556,ROS and RNS production in phagocytes,2/75,24/3769,0.08333333333333333,4.187777777777778,2.2320575184280274,0.08138825755965476,0.33835567749519396,0.2810806766105167,SLC11A1/RAC2,2
R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,2/75,24/3769,0.08333333333333333,4.187777777777778,2.2320575184280274,0.08138825755965476,0.33835567749519396,0.2810806766105167,ANGPTL4/CEBPD,2
R-HSA-8848021,Signaling by PTK6,2/75,24/3769,0.08333333333333333,4.187777777777778,2.2320575184280274,0.08138825755965476,0.33835567749519396,0.2810806766105167,CDK2/SOCS3,2
R-HSA-9006927,Signaling by Non-Receptor Tyrosine Kinases,2/75,24/3769,0.08333333333333333,4.187777777777778,2.2320575184280274,0.08138825755965476,0.33835567749519396,0.2810806766105167,CDK2/SOCS3,2
R-HSA-453274,Mitotic G2-G2/M phases,3/75,54/3769,0.05555555555555555,2.791851851851852,1.8895448465166922,0.09131977213637806,0.339213481508848,0.2817932762463261,CDK2/CDKN1A/PLK4,3
R-HSA-69275,G2/M Transition,3/75,54/3769,0.05555555555555555,2.791851851851852,1.8895448465166922,0.09131977213637806,0.339213481508848,0.2817932762463261,CDK2/CDKN1A/PLK4,3
R-HSA-446728,Cell junction organization,3/75,55/3769,0.05454545454545454,2.741090909090909,1.8531879863984275,0.09526413230505927,0.339213481508848,0.2817932762463261,FOXF1/ANGPTL4/CDH5,3
R-HSA-8957275,Post-translational protein phosphorylation,3/75,55/3769,0.05454545454545454,2.741090909090909,1.8531879863984275,0.09526413230505927,0.339213481508848,0.2817932762463261,CP/TIMP1/IL6,3
R-HSA-198323,AKT phosphorylates targets in the cytosol,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,CDKN1A,1
R-HSA-211958,Miscellaneous substrates,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,CYP3A43,1
R-HSA-389948,Co-inhibition by PD-1,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,HLA-DRB5,1
R-HSA-430116,GP1b-IX-V activation signalling,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,VWF,1
R-HSA-75892,Platelet Adhesion to exposed collagen,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,VWF,1
R-HSA-877312,Regulation of IFNG signaling,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,SOCS3,1
R-HSA-8939242,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,SOCS3,1
R-HSA-8941855,RUNX3 regulates CDKN1A transcription,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,CDKN1A,1
R-HSA-9702518,STAT5 activation downstream of FLT3 ITD mutants,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,CDKN1A,1
R-HSA-9762293,Regulation of CDH11 gene transcription,1/75,5/3769,0.2,10.050666666666668,2.885216440717041,0.09566288637916509,0.339213481508848,0.2817932762463261,FOXF1,1
R-HSA-2559586,DNA Damage/Telomere Stress Induced Senescence,2/75,27/3769,0.07407407407407407,3.7224691358024686,2.022695874290816,0.09967951253578737,0.339213481508848,0.2817932762463261,CDK2/CDKN1A,2
R-HSA-917937,Iron uptake and transport,2/75,27/3769,0.07407407407407407,3.7224691358024686,2.022695874290816,0.09967951253578737,0.339213481508848,0.2817932762463261,CP/STEAP4,2
R-HSA-9755511,KEAP1-NFE2L2 pathway,2/75,27/3769,0.07407407407407407,3.7224691358024686,2.022695874290816,0.09967951253578737,0.339213481508848,0.2817932762463261,CCL2/CDKN1A,2
R-HSA-3781865,Diseases of glycosylation,3/75,57/3769,0.05263157894736842,2.644912280701754,1.7828459560147552,0.1033597821648168,0.339213481508848,0.2817932762463261,THBS1/ADAMTS1/ADAMTS9,3
R-HSA-186797,Signaling by PDGF,2/75,28/3769,0.07142857142857142,3.5895238095238096,1.9594884291348753,0.10601250415434997,0.339213481508848,0.2817932762463261,THBS1/COL4A1,2
R-HSA-6802952,Signaling by BRAF and RAF1 fusions,2/75,28/3769,0.07142857142857142,3.5895238095238096,1.9594884291348753,0.10601250415434997,0.339213481508848,0.2817932762463261,VWF/ITGB3,2
R-HSA-3700989,Transcriptional Regulation by TP53,4/75,91/3769,0.04395604395604396,2.2089377289377294,1.6632456577993167,0.10610865332176893,0.339213481508848,0.2817932762463261,TNFRSF10B/CDK2/CDKN1A/TNFRSF10D,4
R-HSA-2559583,Cellular Senescence,3/75,58/3769,0.05172413793103448,2.599310344827586,1.7487949851139897,0.10750795655212146,0.339213481508848,0.2817932762463261,CDK2/CDKN1A/IL6,3
R-HSA-194313,VEGF ligand-receptor interactions,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,FLT1,1
R-HSA-195399,VEGF binds to VEGFR leading to receptor dimerization,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,FLT1,1
R-HSA-204174,Regulation of pyruvate dehydrogenase (PDH) complex,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,PDK1,1
R-HSA-210990,PECAM1 interactions,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,ITGB3,1
R-HSA-3371378,Regulation by c-FLIP,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,TNFRSF10B,1
R-HSA-380994,ATF4 activates genes in response to endoplasmic reticulum  stress,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,CCL2,1
R-HSA-381042,PERK regulates gene expression,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,CCL2,1
R-HSA-419812,Calcitonin-like ligand receptors,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,ADM,1
R-HSA-448706,Interleukin-1 processing,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,IL1B,1
R-HSA-5218900,CASP8 activity is inhibited,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,TNFRSF10B,1
R-HSA-69017,CDK-mediated phosphorylation and removal of Cdc6,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,CDK2,1
R-HSA-69416,Dimerization of procaspase-8,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,TNFRSF10B,1
R-HSA-9762292,Regulation of CDH11 function,1/75,6/3769,0.16666666666666666,8.375555555555556,2.575970515961814,0.11368235596512744,0.339213481508848,0.2817932762463261,ANGPTL4,1
R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),3/75,61/3769,0.04918032786885246,2.4714754098360654,1.650766689974094,0.12033482659108594,0.35619108670961436,0.2958970051755545,CP/TIMP1/IL6,3
R-HSA-9020702,Interleukin-1 signaling,2/75,31/3769,0.06451612903225806,3.2421505376344086,1.7859265732696523,0.12562369489548048,0.3654027354909486,0.3035493563680142,IL1R1/IL1B,2
R-HSA-9730414,MITF-M-regulated melanocyte development,3/75,63/3769,0.047619047619047616,2.3930158730158726,1.5885879558656193,0.1291885564292214,0.3654027354909486,0.3035493563680142,EDN1/CDK2/CDKN1A,3
R-HSA-3232118,SUMOylation of transcription factors,1/75,7/3769,0.14285714285714285,7.179047619047619,2.331303414369389,0.13134746978458423,0.3654027354909486,0.3035493563680142,HIC1,1
R-HSA-419408,Lysosphingolipid and LPA receptors,1/75,7/3769,0.14285714285714285,7.179047619047619,2.331303414369389,0.13134746978458423,0.3654027354909486,0.3035493563680142,S1PR3,1
R-HSA-8853884,Transcriptional Regulation by VENTX,1/75,7/3769,0.14285714285714285,7.179047619047619,2.331303414369389,0.13134746978458423,0.3654027354909486,0.3035493563680142,IL6,1
R-HSA-912694,Regulation of IFNA/IFNB signaling,1/75,7/3769,0.14285714285714285,7.179047619047619,2.331303414369389,0.13134746978458423,0.3654027354909486,0.3035493563680142,SOCS3,1
R-HSA-9617828,FOXO-mediated transcription of cell cycle genes,1/75,7/3769,0.14285714285714285,7.179047619047619,2.331303414369389,0.13134746978458423,0.3654027354909486,0.3035493563680142,CDKN1A,1
R-HSA-9651496,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),1/75,7/3769,0.14285714285714285,7.179047619047619,2.331303414369389,0.13134746978458423,0.3654027354909486,0.3035493563680142,VWF,1
R-HSA-9843745,Adipogenesis,2/75,32/3769,0.0625,3.140833333333333,1.7327421167187118,0.1323435428534602,0.3654262004162707,0.3035688492789504,ANGPTL4/CEBPD,2
R-HSA-6802957,Oncogenic MAPK signaling,2/75,33/3769,0.06060606060606061,3.0456565656565657,1.681604626293341,0.13914465754246563,0.36916837895991456,0.30667757227964454,VWF/ITGB3,2
R-HSA-69206,G1/S Transition,2/75,33/3769,0.06060606060606061,3.0456565656565657,1.681604626293341,0.13914465754246563,0.36916837895991456,0.30667757227964454,CDK2/CDKN1A,2
R-HSA-69242,S Phase,2/75,33/3769,0.06060606060606061,3.0456565656565657,1.681604626293341,0.13914465754246563,0.36916837895991456,0.30667757227964454,CDK2/CDKN1A,2
R-HSA-597592,Post-translational protein modification,12/75,430/3769,0.027906976744186046,1.4024186046511629,1.2631115381782472,0.14087365964981324,0.36916837895991456,0.30667757227964454,PLAUR/CP/TIMP1/CISH/CDKN1A/IL6/THBS1/RAB20/ADAMTS1/ADAMTS9/HIC1/SOCS3,12
R-HSA-168249,Innate Immune System,11/75,389/3769,0.028277634961439587,1.4210454155955439,1.2493468518243898,0.14540997253859936,0.36916837895991456,0.30667757227964454,PLAUR/SLC11A1/CRISPLD2/IL1B/CD93/RAC2/FPR2/FPR1/ANXA2/SERPINA3/CASP4,11
R-HSA-9856530,High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,2/75,34/3769,0.058823529411764705,2.956078431372549,1.632367926690136,0.146021263057156,0.36916837895991456,0.30667757227964454,ADM/CDH5,2
R-HSA-176408,Regulation of APC/C activators between G1/S and early anaphase,1/75,8/3769,0.125,6.281666666666666,2.1306001280943465,0.14866510395953314,0.36916837895991456,0.30667757227964454,CDK2,1
R-HSA-180786,Extension of Telomeres,1/75,8/3769,0.125,6.281666666666666,2.1306001280943465,0.14866510395953314,0.36916837895991456,0.30667757227964454,CDK2,1
R-HSA-425381,Bicarbonate transporters,1/75,8/3769,0.125,6.281666666666666,2.1306001280943465,0.14866510395953314,0.36916837895991456,0.30667757227964454,SLC4A5,1
R-HSA-445144,Signal transduction by L1,1/75,8/3769,0.125,6.281666666666666,2.1306001280943465,0.14866510395953314,0.36916837895991456,0.30667757227964454,ITGB3,1
R-HSA-5576890,Phase 3 - rapid repolarisation,1/75,8/3769,0.125,6.281666666666666,2.1306001280943465,0.14866510395953314,0.36916837895991456,0.30667757227964454,KCNE4,1
R-HSA-5674400,Constitutive Signaling by AKT1 E17K in Cancer,1/75,8/3769,0.125,6.281666666666666,2.1306001280943465,0.14866510395953314,0.36916837895991456,0.30667757227964454,CDKN1A,1
R-HSA-6804757,Regulation of TP53 Degradation,1/75,8/3769,0.125,6.281666666666666,2.1306001280943465,0.14866510395953314,0.36916837895991456,0.30667757227964454,CDK2,1
R-HSA-8963889,Assembly of active LPL and LIPC lipase complexes,1/75,8/3769,0.125,6.281666666666666,2.1306001280943465,0.14866510395953314,0.36916837895991456,0.30667757227964454,ANGPTL4,1
R-HSA-9671793,Diseases of hemostasis,1/75,8/3769,0.125,6.281666666666666,2.1306001280943465,0.14866510395953314,0.36916837895991456,0.30667757227964454,VWF,1
R-HSA-983231,Factors involved in megakaryocyte development and platelet production,3/75,68/3769,0.04411764705882353,2.217058823529412,1.4429261903326556,0.15228613364805096,0.37459498656230517,0.3111855933888852,CDK2/IRF1/MAFF,3
R-HSA-112409,RAF-independent MAPK1/3 activation,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,IL6,1
R-HSA-140534,Caspase activation via Death Receptors in the presence of ligand,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,TNFRSF10B,1
R-HSA-140875,Common Pathway of Fibrin Clot Formation,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,THBD,1
R-HSA-1538133,G0 and Early G1,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,CDK2,1
R-HSA-174143,APC/C-mediated degradation of cell cycle proteins,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,CDK2,1
R-HSA-211981,Xenobiotics,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,CYP3A43,1
R-HSA-2214320,Anchoring fibril formation,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,COL4A1,1
R-HSA-453276,Regulation of mitotic cell cycle,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,CDK2,1
R-HSA-6806003,Regulation of TP53 Expression and Degradation,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,CDK2,1
R-HSA-68949,Orc1 removal from chromatin,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,CDK2,1
R-HSA-9703465,Signaling by FLT3 fusion proteins,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,CDKN1A,1
R-HSA-9703648,Signaling by FLT3 ITD and TKD mutants,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,CDKN1A,1
R-HSA-9861718,Regulation of pyruvate metabolism,1/75,9/3769,0.1111111111111111,5.583703703703704,1.9614692405980865,0.16564200297655884,0.37459498656230517,0.3111855933888852,PDK1,1
R-HSA-1500931,Cell-Cell communication,3/75,71/3769,0.04225352112676056,2.123380281690141,1.36147650379573,0.16673933829107832,0.37459498656230517,0.3111855933888852,FOXF1/ANGPTL4/CDH5,3
R-HSA-9616222,Transcriptional regulation of granulopoiesis,2/75,37/3769,0.05405405405405406,2.7163963963963966,1.4948075122354088,0.1670491156291361,0.37459498656230517,0.3111855933888852,CDK2/CDKN1A,2
R-HSA-453279,Mitotic G1 phase and G1/S transition,2/75,38/3769,0.05263157894736842,2.644912280701754,1.4519763748175982,0.17417368983718437,0.38821846529974835,0.3225029640612419,CDK2/CDKN1A,2
R-HSA-140837,Intrinsic Pathway of Fibrin Clot Formation,1/75,10/3769,0.1,5.025333333333334,1.8159476308545077,0.182284782172505,0.39212424071992347,0.32574759115282415,VWF,1
R-HSA-1592389,Activation of Matrix Metalloproteinases,1/75,10/3769,0.1,5.025333333333334,1.8159476308545077,0.182284782172505,0.39212424071992347,0.32574759115282415,TIMP1,1
R-HSA-202424,Downstream TCR signaling,1/75,10/3769,0.1,5.025333333333334,1.8159476308545077,0.182284782172505,0.39212424071992347,0.32574759115282415,HLA-DRB5,1
R-HSA-202433,Generation of second messenger molecules,1/75,10/3769,0.1,5.025333333333334,1.8159476308545077,0.182284782172505,0.39212424071992347,0.32574759115282415,HLA-DRB5,1
R-HSA-2243919,Crosslinking of collagen fibrils,1/75,10/3769,0.1,5.025333333333334,1.8159476308545077,0.182284782172505,0.39212424071992347,0.32574759115282415,COL4A1,1
R-HSA-9682385,FLT3 signaling in disease,1/75,10/3769,0.1,5.025333333333334,1.8159476308545077,0.182284782172505,0.39212424071992347,0.32574759115282415,CDKN1A,1
R-HSA-418594,G alpha (i) signalling events,5/75,152/3769,0.03289473684210526,1.6530701754385964,1.1709679909226465,0.18368511353528366,0.3928525549598552,0.32635262033649426,CXCL2/CXCL11/FPR2/FPR1/S1PR3,5
R-HSA-176187,Activation of ATR in response to replication stress,1/75,11/3769,0.09090909090909091,4.568484848484848,1.688649224944086,0.1985999301738518,0.4128200795748605,0.34294015145336926,CDK2,1
R-HSA-3000480,Scavenging by Class A Receptors,1/75,11/3769,0.09090909090909091,4.568484848484848,1.688649224944086,0.1985999301738518,0.4128200795748605,0.34294015145336926,COL4A1,1
R-HSA-5576893,Phase 2 - plateau phase,1/75,11/3769,0.09090909090909091,4.568484848484848,1.688649224944086,0.1985999301738518,0.4128200795748605,0.34294015145336926,KCNE4,1
R-HSA-69052,Switching of origins to a post-replicative state,1/75,11/3769,0.09090909090909091,4.568484848484848,1.688649224944086,0.1985999301738518,0.4128200795748605,0.34294015145336926,CDK2,1
R-HSA-8950505,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,1/75,11/3769,0.09090909090909091,4.568484848484848,1.688649224944086,0.1985999301738518,0.4128200795748605,0.34294015145336926,ANXA2,1
R-HSA-425407,SLC-mediated transmembrane transport,4/75,117/3769,0.03418803418803419,1.7180626780626782,1.1241584624770793,0.20272778779897804,0.4175238561106503,0.34684769839063984,SLC11A1/CP/SLC16A3/SLC4A5,4
R-HSA-9856651,MITF-M-dependent gene expression,2/75,42/3769,0.047619047619047616,2.3930158730158726,1.2934172452549342,0.2031197137835596,0.4175238561106503,0.34684769839063984,CDK2/CDKN1A,2
R-HSA-3000178,ECM proteoglycans,2/75,43/3769,0.046511627906976744,2.337364341085271,1.2566090261072365,0.21044585849437572,0.4291876225813178,0.3565370861841958,COL4A1/ITGB3,2
R-HSA-210991,Basigin interactions,1/75,12/3769,0.08333333333333333,4.187777777777778,1.575780411621898,0.2145938112906589,0.4291876225813178,0.3565370861841958,SLC16A3,1
R-HSA-6803157,Antimicrobial peptides,1/75,12/3769,0.08333333333333333,4.187777777777778,1.575780411621898,0.2145938112906589,0.4291876225813178,0.3565370861841958,SLC11A1,1
R-HSA-68962,Activation of the pre-replicative complex,1/75,12/3769,0.08333333333333333,4.187777777777778,1.575780411621898,0.2145938112906589,0.4291876225813178,0.3565370861841958,CDK2,1
R-HSA-9856532,Mechanical load activates signaling by PIEZO1 and integrins in osteocytes,1/75,12/3769,0.08333333333333333,4.187777777777778,1.575780411621898,0.2145938112906589,0.4291876225813178,0.3565370861841958,ITGB3,1
R-HSA-4420097,VEGFA-VEGFR2 Pathway,2/75,44/3769,0.045454545454545456,2.284242424242424,1.2208093460100873,0.2177994835041544,0.4332570370781566,0.35991765242339047,CDH5/ITGB3,2
R-HSA-3295583,TRP channels,1/75,13/3769,0.07692307692307693,3.8656410256410263,1.47457987929257,0.2302726678659055,0.4437546203665887,0.3686382621537523,MLKL,1
R-HSA-450531,Regulation of mRNA stability by proteins that bind AU-rich elements,1/75,13/3769,0.07692307692307693,3.8656410256410263,1.47457987929257,0.2302726678659055,0.4437546203665887,0.3686382621537523,ZFP36,1
R-HSA-5218920,VEGFR2 mediated vascular permeability,1/75,13/3769,0.07692307692307693,3.8656410256410263,1.47457987929257,0.2302726678659055,0.4437546203665887,0.3686382621537523,CDH5,1
R-HSA-5357769,Caspase activation via extrinsic apoptotic signalling pathway,1/75,13/3769,0.07692307692307693,3.8656410256410263,1.47457987929257,0.2302726678659055,0.4437546203665887,0.3686382621537523,TNFRSF10B,1
R-HSA-70268,Pyruvate metabolism,1/75,13/3769,0.07692307692307693,3.8656410256410263,1.47457987929257,0.2302726678659055,0.4437546203665887,0.3686382621537523,PDK1,1
R-HSA-75876,Synthesis of very long-chain fatty acyl-CoAs,1/75,13/3769,0.07692307692307693,3.8656410256410263,1.47457987929257,0.2302726678659055,0.4437546203665887,0.3686382621537523,ACSL5,1
R-HSA-168638,NOD1/2 Signaling Pathway,1/75,14/3769,0.07142857142857142,3.5895238095238096,1.3829821950178482,0.24564262258104275,0.45217796196510357,0.3756357464973265,CASP4,1
R-HSA-449836,Other interleukin signaling,1/75,14/3769,0.07142857142857142,3.5895238095238096,1.3829821950178482,0.24564262258104275,0.45217796196510357,0.3756357464973265,CSF3,1
R-HSA-5668599,RHO GTPases Activate NADPH Oxidases,1/75,14/3769,0.07142857142857142,3.5895238095238096,1.3829821950178482,0.24564262258104275,0.45217796196510357,0.3756357464973265,RAC2,1
R-HSA-75105,Fatty acyl-CoA biosynthesis,1/75,14/3769,0.07142857142857142,3.5895238095238096,1.3829821950178482,0.24564262258104275,0.45217796196510357,0.3756357464973265,ACSL5,1
R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,1/75,14/3769,0.07142857142857142,3.5895238095238096,1.3829821950178482,0.24564262258104275,0.45217796196510357,0.3756357464973265,CDKN1A,1
R-HSA-9020591,Interleukin-12 signaling,1/75,14/3769,0.07142857142857142,3.5895238095238096,1.3829821950178482,0.24564262258104275,0.45217796196510357,0.3756357464973265,ANXA2,1
R-HSA-9660826,Purinergic signaling in leishmaniasis infection,1/75,14/3769,0.07142857142857142,3.5895238095238096,1.3829821950178482,0.24564262258104275,0.45217796196510357,0.3756357464973265,IL1B,1
R-HSA-9664424,Cell recruitment (pro-inflammatory response),1/75,14/3769,0.07142857142857142,3.5895238095238096,1.3829821950178482,0.24564262258104275,0.45217796196510357,0.3756357464973265,IL1B,1
R-HSA-9839373,Signaling by TGFBR3,1/75,14/3769,0.07142857142857142,3.5895238095238096,1.3829821950178482,0.24564262258104275,0.45217796196510357,0.3756357464973265,TIMP1,1
R-HSA-446652,Interleukin-1 family signaling,2/75,48/3769,0.041666666666666664,2.093888888888889,1.086679884484087,0.2474123154006971,0.45318097375375216,0.3764689739291483,IL1R1/IL1B,2
R-HSA-114604,GPVI-mediated activation cascade,1/75,15/3769,0.06666666666666667,3.350222222222222,1.2994065659930687,0.2607096807185717,0.4705491798335197,0.3908971849541615,RAC2,1
R-HSA-447115,Interleukin-12 family signaling,1/75,15/3769,0.06666666666666667,3.350222222222222,1.2994065659930687,0.2607096807185717,0.4705491798335197,0.3908971849541615,ANXA2,1
R-HSA-69273,Cyclin A/B1/B2 associated events during G2/M transition,1/75,15/3769,0.06666666666666667,3.350222222222222,1.2994065659930687,0.2607096807185717,0.4705491798335197,0.3908971849541615,CDK2,1
R-HSA-9711123,Cellular response to chemical stress,2/75,51/3769,0.0392156862745098,1.970718954248366,0.9944009677110106,0.2697316521286114,0.484469472269836,0.40246112632373293,CCL2/CDKN1A,2
R-HSA-5668914,Diseases of metabolism,3/75,91/3769,0.03296703296703297,1.6567032967032966,0.9034864911230807,0.271047623806486,0.48448125994396046,0.4024709186447695,THBS1/ADAMTS1/ADAMTS9,3
R-HSA-9837999,Mitochondrial protein degradation,1/75,16/3769,0.0625,3.140833333333333,1.2226191686970507,0.27547973238242573,0.49003606241104575,0.4070854344922486,PDK1,1
R-HSA-2219528,PI3K/AKT Signaling in Cancer,2/75,52/3769,0.038461538461538464,1.9328205128205131,0.9650306614149787,0.27717509383811667,0.49069274985695294,0.4076309614743394,CDKN1A/RAC2,2
R-HSA-190861,Gap junction assembly,1/75,17/3769,0.058823529411764705,2.956078431372549,1.1516405371409089,0.2899585546769421,0.5060597416531536,0.4203967128384663,GJA4,1
R-HSA-445355,Smooth Muscle Contraction,1/75,17/3769,0.058823529411764705,2.956078431372549,1.1516405371409089,0.2899585546769421,0.5060597416531536,0.4203967128384663,ANXA2,1
R-HSA-8852276,The role of GTSE1 in G2/M progression after G2 checkpoint,1/75,17/3769,0.058823529411764705,2.956078431372549,1.1516405371409089,0.2899585546769421,0.5060597416531536,0.4203967128384663,CDKN1A,1
R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,1/75,18/3769,0.05555555555555555,2.791851851851852,1.0856815400711792,0.30415181384518,0.519993680960568,0.4319719910113396,COL4A1,1
R-HSA-380259,Loss of Nlp from mitotic centrosomes,1/75,18/3769,0.05555555555555555,2.791851851851852,1.0856815400711792,0.30415181384518,0.519993680960568,0.4319719910113396,PLK4,1
R-HSA-380284,Loss of proteins required for interphase microtubule organization from the centrosome,1/75,18/3769,0.05555555555555555,2.791851851851852,1.0856815400711792,0.30415181384518,0.519993680960568,0.4319719910113396,PLK4,1
R-HSA-8963899,Plasma lipoprotein remodeling,1/75,18/3769,0.05555555555555555,2.791851851851852,1.0856815400711792,0.30415181384518,0.519993680960568,0.4319719910113396,ANGPTL4,1
R-HSA-372790,Signaling by GPCR,9/75,367/3769,0.02452316076294278,1.2323705722070846,0.667551287902165,0.30496926694173854,0.519993680960568,0.4319719910113396,EDN1/CXCL2/CCL2/ADM/CXCL11/FPR2/FPR1/GPR4/S1PR3,9
R-HSA-9006936,Signaling by TGFB family members,2/75,56/3769,0.03571428571428571,1.7947619047619048,0.8537018332645993,0.3068904918288652,0.5208691833792666,0.43269929316286165,TIMP1/ITGB3,2
R-HSA-2173789,TGF-beta receptor signaling activates SMADs,1/75,19/3769,0.05263157894736842,2.644912280701754,1.024098058546424,0.31806506736733686,0.5253753344906903,0.43644266762811273,ITGB3,1
R-HSA-3000157,Laminin interactions,1/75,19/3769,0.05263157894736842,2.644912280701754,1.024098058546424,0.31806506736733686,0.5253753344906903,0.43644266762811273,COL4A1,1
R-HSA-381119,Unfolded Protein Response (UPR),1/75,19/3769,0.05263157894736842,2.644912280701754,1.024098058546424,0.31806506736733686,0.5253753344906903,0.43644266762811273,CCL2,1
R-HSA-5362517,Signaling by Retinoic Acid,1/75,19/3769,0.05263157894736842,2.644912280701754,1.024098058546424,0.31806506736733686,0.5253753344906903,0.43644266762811273,PDK1,1
R-HSA-69239,Synthesis of DNA,1/75,19/3769,0.05263157894736842,2.644912280701754,1.024098058546424,0.31806506736733686,0.5253753344906903,0.43644266762811273,CDK2,1
R-HSA-917977,Transferrin endocytosis and recycling,1/75,19/3769,0.05263157894736842,2.644912280701754,1.024098058546424,0.31806506736733686,0.5253753344906903,0.43644266762811273,STEAP4,1
R-HSA-388396,GPCR downstream signalling,8/75,327/3769,0.024464831804281346,1.2294393476044851,0.61854880989398775,0.3239189445113513,0.5326667087519998,0.4424997978821735,EDN1/CXCL2/ADM/CXCL11/FPR2/FPR1/GPR4/S1PR3,8
R-HSA-5684996,MAPK1/MAPK3 signaling,3/75,102/3769,0.029411764705882353,1.4780392156862745,0.6973419458976619,0.3314593625288529,0.54066252611187815,0.4491421269549599,VWF/IL6/ITGB3,3
R-HSA-8854518,AURKA Activation by TPX2,1/75,20/3769,0.05,2.512666666666667,0.9663582254959752,0.3317037660199901,0.54066252611187815,0.4491421269549599,PLK4,1
R-HSA-73887,Death Receptor Signaling,2/75,60/3769,0.03333333333333333,1.675111111111111,0.7510348631440972,0.336390041590367,0.5458961201247183,0.45348980676079037,TNFRSF10B/TNFRSF10D,2
R-HSA-2565942,Regulation of PLK1 Activity at G2/M Transition,1/75,21/3769,0.047619047619047616,2.3930158730158726,0.9120183039347515,0.345073255896891,0.5551178464428246,0.4611505296196438,PLK4,1
R-HSA-5607764,CLEC7A (Dectin-1) signaling,1/75,21/3769,0.047619047619047616,2.3930158730158726,0.9120183039347515,0.345073255896891,0.5551178464428246,0.4611505296196438,IL1B,1
R-HSA-392499,Metabolism of proteins,13/75,572/3769,0.022727272727272728,1.142121212121212,0.525803209006486,0.34660579460498686,0.5551694545621001,0.46119340179838775,PLAUR/CP/TIMP1/CISH/CDKN1A/IL6/THBS1/RAB20/PDK1/ADAMTS1/ADAMTS9/HIC1/SOCS3,13
R-HSA-1643685,Disease,14/75,622/3769,0.022508038585209004,1.1311039657020365,0.509800530135005,0.35123769939856314,0.5591820622153857,0.46452677714620955,CP/VWF/IL1R1/CDK2/CDKN1A/IL1B/RAC2/IL6/THBS1/ADAMTS1/ADAMTS9/MLKL/CEBPD/ITGB3,14
R-HSA-212436,Generic Transcription Pathway,8/75,337/3769,0.02373887240356083,1.1929574678536103,0.5288597743692178,0.3547709115946003,0.5591820622153857,0.46452677714620955,TNFRSF10B/CDK2/CDKN1A/IL6/THBS1/TNFRSF10D/SOCS3/ZIM2,8
R-HSA-2129379,Molecules associated with elastic fibres,1/75,22/3769,0.045454545454545456,2.284242424242424,0.8607046307672815,0.35817878039201734,0.5591820622153857,0.46452677714620955,ITGB3,1
R-HSA-380270,Recruitment of mitotic centrosome proteins and complexes,1/75,22/3769,0.045454545454545456,2.284242424242424,0.8607046307672815,0.35817878039201734,0.5591820622153857,0.46452677714620955,PLK4,1
R-HSA-380287,Centrosome maturation,1/75,22/3769,0.045454545454545456,2.284242424242424,0.8607046307672815,0.35817878039201734,0.5591820622153857,0.46452677714620955,PLK4,1
R-HSA-9759194,Nuclear events mediated by NFE2L2,1/75,22/3769,0.045454545454545456,2.284242424242424,0.8607046307672815,0.35817878039201734,0.5591820622153857,0.46452677714620955,CCL2,1
R-HSA-168643,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",1/75,23/3769,0.043478260869565216,2.1849275362318843,0.8120998995035686,0.3710254821455794,0.5649359193163143,0.4693066527464119,CASP4,1
R-HSA-190828,Gap junction trafficking,1/75,23/3769,0.043478260869565216,2.1849275362318843,0.8120998995035686,0.3710254821455794,0.5649359193163143,0.4693066527464119,GJA4,1
R-HSA-388841,Regulation of T cell activation by CD28 family,1/75,23/3769,0.043478260869565216,2.1849275362318843,0.8120998995035686,0.3710254821455794,0.5649359193163143,0.4693066527464119,HLA-DRB5,1
R-HSA-6804756,Regulation of TP53 Activity through Phosphorylation,1/75,23/3769,0.043478260869565216,2.1849275362318843,0.8120998995035686,0.3710254821455794,0.5649359193163143,0.4693066527464119,CDK2,1
R-HSA-8873719,RAB geranylgeranylation,1/75,23/3769,0.043478260869565216,2.1849275362318843,0.8120998995035686,0.3710254821455794,0.5649359193163143,0.4693066527464119,RAB20,1
R-HSA-9660821,ADORA2B mediated anti-inflammatory cytokines production,1/75,23/3769,0.043478260869565216,2.1849275362318843,0.8120998995035686,0.3710254821455794,0.5649359193163143,0.4693066527464119,IL6,1
R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2/75,65/3769,0.03076923076923077,1.5462564102564103,0.6329295450212842,0.3727456122718633,0.5652290022155304,0.46955012417335684,CLEC2B/IFITM1,2
R-HSA-157858,Gap junction trafficking and regulation,1/75,24/3769,0.041666666666666664,2.093888888888889,0.7659325991259647,0.3836184049536633,0.5769870318408757,0.4793178187696606,GJA4,1
R-HSA-5620912,Anchoring of the basal body to the plasma membrane,1/75,24/3769,0.041666666666666664,2.093888888888889,0.7659325991259647,0.3836184049536633,0.5769870318408757,0.4793178187696606,PLK4,1
R-HSA-8878171,Transcriptional regulation by RUNX1,2/75,67/3769,0.029850746268656716,1.5000995024875623,0.5884549898654509,0.38707830082189243,0.579833891919434,0.481682777924537,THBS1/SOCS3,2
R-HSA-9614085,FOXO-mediated transcription,1/75,25/3769,0.04,2.010133333333333,0.7219687837795215,0.3959624956421748,0.5899038393724038,0.4900481396777863,CDKN1A,1
R-HSA-74160,Gene expression (Transcription),9/75,399/3769,0.022556390977443608,1.133533834586466,0.40188375467737264,0.3981643873370475,0.5899038393724038,0.4900481396777863,TNFRSF10B/CDK2/CDKN1A/IL6/THBS1/ANGPTL4/TNFRSF10D/SOCS3/ZIM2,9
R-HSA-73857,RNA Polymerase II Transcription,8/75,351/3769,0.022792022792022793,1.145375118708452,0.4074696296908455,0.39858367525162414,0.5899038393724038,0.4900481396777863,TNFRSF10B/CDK2/CDKN1A/IL6/THBS1/TNFRSF10D/SOCS3/ZIM2,8
R-HSA-9856649,Transcriptional and post-translational regulation of MITF-M expression and activity,1/75,26/3769,0.038461538461538464,1.9328205128205131,0.6800055876288778,0.40806260590575305,0.5971375140459396,0.4960573374151192,EDN1,1
R-HSA-5683057,MAPK family signaling cascades,3/75,116/3769,0.02586206896551724,1.299655172413793,0.467050208466103,0.4081768458421754,0.5971375140459396,0.4960573374151192,VWF/IL6/ITGB3,3
R-HSA-69620,Cell Cycle Checkpoints,2/75,70/3769,0.02857142857142857,1.4358095238095239,0.5243740655749796,0.40831294879357494,0.5971375140459396,0.4960573374151192,CDK2/CDKN1A,2
R-HSA-1566948,Elastic fibre formation,1/75,27/3769,0.037037037037037035,1.8612345679012343,0.6398660628991806,0.41992349411229,0.6069206750841691,0.5041844583914009,ITGB3,1
R-HSA-380320,Recruitment of NuMA to mitotic centrosomes,1/75,27/3769,0.037037037037037035,1.8612345679012343,0.6398660628991806,0.41992349411229,0.6069206750841691,0.5041844583914009,PLK4,1
R-HSA-5693607,Processing of DNA double-strand break ends,1/75,27/3769,0.037037037037037035,1.8612345679012343,0.6398660628991806,0.41992349411229,0.6069206750841691,0.5041844583914009,CDK2,1
R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,4/75,166/3769,0.024096385542168676,1.2109236947791164,0.3959906361911395,0.42245900498818156,0.608209462434347,0.5052550868586894,VWF/CDKN1A/RAC2/ITGB3,4
R-HSA-211897,Cytochrome P450 - arranged by substrate type,1/75,28/3769,0.03571428571428571,1.7947619047619048,0.6013950327742014,0.4315498270736955,0.6141286000664128,0.5101722652045307,CYP3A43,1
R-HSA-419037,NCAM1 interactions,1/75,28/3769,0.03571428571428571,1.7947619047619048,0.6013950327742014,0.4315498270736955,0.6141286000664128,0.5101722652045307,COL4A1,1
R-HSA-5619102,SLC transporter disorders,1/75,28/3769,0.03571428571428571,1.7947619047619048,0.6013950327742014,0.4315498270736955,0.6141286000664128,0.5101722652045307,CP,1
R-HSA-4086400,PCP/CE pathway,1/75,29/3769,0.034482758620689655,1.7328735632183907,0.5644557309619643,0.4429461817835252,0.6279313688118939,0.5216385766517014,RAC2,1
R-HSA-9658195,Leishmania infection,2/75,77/3769,0.025974025974025976,1.3052813852813854,0.3856137162695363,0.45644512984651453,0.6421471408487087,0.5334479804489984,IL1B/IL6,2
R-HSA-9824443,Parasitic Infection Pathways,2/75,77/3769,0.025974025974025976,1.3052813852813854,0.3856137162695363,0.45644512984651453,0.6421471408487087,0.5334479804489984,IL1B/IL6,2
R-HSA-157579,Telomere Maintenance,1/75,31/3769,0.03225806451612903,1.6210752688172043,0.4947013182047531,0.4650668255296445,0.6468974640825882,0.5373941949135586,CDK2,1
R-HSA-8948216,Collagen chain trimerization,1/75,31/3769,0.03225806451612903,1.6210752688172043,0.4947013182047531,0.4650668255296445,0.6468974640825882,0.5373941949135586,COL4A1,1
R-HSA-912446,Meiotic recombination,1/75,31/3769,0.03225806451612903,1.6210752688172043,0.4947013182047531,0.4650668255296445,0.6468974640825882,0.5373941949135586,CDK2,1
R-HSA-416476,G alpha (q) signalling events,3/75,128/3769,0.0234375,1.1778125,0.2916047316259893,0.471941367314594,0.6540011457168532,0.5432954041232465,EDN1/FPR2/GPR4,3
R-HSA-170834,Signaling by TGF-beta Receptor Complex,1/75,32/3769,0.03125,1.5704166666666666,0.46168235846397754,0.47579983464823106,0.6544458692187565,0.5436648472599628,ITGB3,1
R-HSA-9925563,Developmental Lineage of Pancreatic Ductal Cells,1/75,32/3769,0.03125,1.5704166666666666,0.46168235846397754,0.47579983464823106,0.6544458692187565,0.5436648472599628,ANXA2,1
R-HSA-382551,Transport of small molecules,7/75,327/3769,0.021406727828746176,1.0757594291539245,0.20424092567674246,0.47887925163142087,0.656241937420836,0.5451568868474655,SLC11A1/CP/STEAP4/SLC16A3/ANGPTL4/MLKL/SLC4A5,7
R-HSA-5693567,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),1/75,33/3769,0.030303030303030304,1.5228282828282829,0.4297839988985943,0.4863203089327861,0.6578732217745261,0.5465120362963347,CDK2,1
R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,1/75,33/3769,0.030303030303030304,1.5228282828282829,0.4297839988985943,0.4863203089327861,0.6578732217745261,0.5465120362963347,THBS1,1
R-HSA-9662361,Sensory processing of sound by outer hair cells of the cochlea,1/75,33/3769,0.030303030303030304,1.5228282828282829,0.4297839988985943,0.4863203089327861,0.6578732217745261,0.5465120362963347,CHRNA10,1
R-HSA-1989781,PPARA activates gene expression,1/75,34/3769,0.029411764705882353,1.4780392156862745,0.3989287294778019,0.49663240123204755,0.6578732217745261,0.5465120362963347,ANGPTL4,1
R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,1/75,34/3769,0.029411764705882353,1.4780392156862745,0.3989287294778019,0.49663240123204755,0.6578732217745261,0.5465120362963347,COL4A1,1
R-HSA-400206,Regulation of lipid metabolism by PPARalpha,1/75,34/3769,0.029411764705882353,1.4780392156862745,0.3989287294778019,0.49663240123204755,0.6578732217745261,0.5465120362963347,ANGPTL4,1
R-HSA-1442490,Collagen degradation,1/75,35/3769,0.02857142857142857,1.4358095238095239,0.36904660571907216,0.5067401843398377,0.6578732217745261,0.5465120362963347,COL4A1,1
R-HSA-375165,NCAM signaling for neurite out-growth,1/75,35/3769,0.02857142857142857,1.4358095238095239,0.36904660571907216,0.5067401843398377,0.6578732217745261,0.5465120362963347,COL4A1,1
R-HSA-5693538,Homology Directed Repair,1/75,35/3769,0.02857142857142857,1.4358095238095239,0.36904660571907216,0.5067401843398377,0.6578732217745261,0.5465120362963347,CDK2,1
R-HSA-73886,Chromosome Maintenance,1/75,35/3769,0.02857142857142857,1.4358095238095239,0.36904660571907216,0.5067401843398377,0.6578732217745261,0.5465120362963347,CDK2,1
R-HSA-8878159,Transcriptional regulation by RUNX3,1/75,35/3769,0.02857142857142857,1.4358095238095239,0.36904660571907216,0.5067401843398377,0.6578732217745261,0.5465120362963347,CDKN1A,1
R-HSA-8878166,Transcriptional regulation by RUNX2,1/75,35/3769,0.02857142857142857,1.4358095238095239,0.36904660571907216,0.5067401843398377,0.6578732217745261,0.5465120362963347,CDKN1A,1
R-HSA-9610379,HCMV Late Events,1/75,35/3769,0.02857142857142857,1.4358095238095239,0.36904660571907216,0.5067401843398377,0.6578732217745261,0.5465120362963347,CEBPD,1
R-HSA-9700206,Signaling by ALK in cancer,1/75,35/3769,0.02857142857142857,1.4358095238095239,0.36904660571907216,0.5067401843398377,0.6578732217745261,0.5465120362963347,CDKN1A,1
R-HSA-9725370,Signaling by ALK fusions and activated point mutants,1/75,35/3769,0.02857142857142857,1.4358095238095239,0.36904660571907216,0.5067401843398377,0.6578732217745261,0.5465120362963347,CDKN1A,1
R-HSA-163125,Post-translational modification: synthesis of GPI-anchored proteins,1/75,36/3769,0.027777777777777776,1.395925925925926,0.34007431322015613,0.5166476525172649,0.663748720247875,0.5513929624818763,PLAUR,1
R-HSA-5621481,C-type lectin receptors (CLRs),1/75,36/3769,0.027777777777777776,1.395925925925926,0.34007431322015613,0.5166476525172649,0.663748720247875,0.5513929624818763,IL1B,1
R-HSA-9009391,Extra-nuclear estrogen signaling,1/75,36/3769,0.027777777777777776,1.395925925925926,0.34007431322015613,0.5166476525172649,0.663748720247875,0.5513929624818763,S1PR3,1
R-HSA-9679191,Potential therapeutics for SARS,1/75,37/3769,0.02702702702702703,1.3581981981981983,0.3119543705987815,0.5263587229863793,0.6738848702593784,0.5598133203861693,IL1R1,1
R-HSA-1500620,Meiosis,1/75,38/3769,0.02631578947368421,1.322456140350877,0.28463444719653863,0.5358772373958172,0.683705440815353,0.5679715184013743,CDK2,1
R-HSA-1650814,Collagen biosynthesis and modifying enzymes,1/75,39/3769,0.02564102564102564,1.2885470085470085,0.2580667764532258,0.5452069632589407,0.6890884750654315,0.5724433420173715,COL4A1,1
R-HSA-174824,"Plasma lipoprotein assembly, remodeling, and clearance",1/75,39/3769,0.02564102564102564,1.2885470085470085,0.2580667764532258,0.5452069632589407,0.6890884750654315,0.5724433420173715,ANGPTL4,1
R-HSA-1257604,PIP3 activates AKT signaling,2/75,91/3769,0.02197802197802198,1.1044688644688647,0.14372732444684433,0.5456835762004634,0.6890884750654315,0.5724433420173715,CDKN1A/RAC2,2
R-HSA-9645723,Diseases of programmed cell death,1/75,40/3769,0.025,1.2563333333333335,0.2322076494390455,0.5543515953649942,0.6976533683164894,0.5795584169229443,MLKL,1
R-HSA-69278,"Cell Cycle, Mitotic",3/75,145/3769,0.020689655172413793,1.0397241379310345,0.06949955454563657,0.5567073754024514,0.6982431488098543,0.580048362595953,CDK2/CDKN1A/PLK4,3
R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,1/75,41/3769,0.024390243902439025,1.2256910569105692,0.20701697586954398,0.5633147571637674,0.701772593099643,0.5829803618352654,IL6,1
R-HSA-9664433,Leishmania parasite growth and survival,1/75,41/3769,0.024390243902439025,1.2256910569105692,0.20701697586954398,0.5633147571637674,0.701772593099643,0.5829803618352654,IL6,1
R-HSA-5633007,Regulation of TP53 Activity,1/75,42/3769,0.023809523809523808,1.1965079365079363,0.1824579021907029,0.5721000021242602,0.7054554271398898,0.5860397858459399,CDK2,1
R-HSA-69002,DNA Replication Pre-Initiation,1/75,42/3769,0.023809523809523808,1.1965079365079363,0.1824579021907029,0.5721000021242602,0.7054554271398898,0.5860397858459399,CDK2,1
R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,5/75,253/3769,0.019762845849802372,0.9931488801054019,-0.01607440951578402,0.5735791427402438,0.7054554271398898,0.5860397858459399,FLT1/THBS1/CDH5/COL4A1/ITGB3,5
R-HSA-1428517,Aerobic respiration and respiratory electron transport,1/75,43/3769,0.023255813953488372,1.1686821705426356,0.15849647813641002,0.580710815067829,0.7054554271398898,0.5860397858459399,PDK1,1
R-HSA-211945,Phase I - Functionalization of compounds,1/75,43/3769,0.023255813953488372,1.1686821705426356,0.15849647813641002,0.580710815067829,0.7054554271398898,0.5860397858459399,CYP3A43,1
R-HSA-9013404,RAC2 GTPase cycle,1/75,43/3769,0.023255813953488372,1.1686821705426356,0.15849647813641002,0.580710815067829,0.7054554271398898,0.5860397858459399,RAC2,1
R-HSA-9758941,Gastrulation,1/75,43/3769,0.023255813953488372,1.1686821705426356,0.15849647813641002,0.580710815067829,0.7054554271398898,0.5860397858459399,FOXF1,1
R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,1/75,44/3769,0.022727272727272728,1.142121212121212,0.13510136462452357,0.5891506134762864,0.7054554271398898,0.5860397858459399,RAC2,1
R-HSA-9659379,Sensory processing of sound,1/75,44/3769,0.022727272727272728,1.142121212121212,0.13510136462452357,0.5891506134762864,0.7054554271398898,0.5860397858459399,CHRNA10,1
R-HSA-9818564,Epigenetic regulation of gene expression by MLL3 and MLL4 complexes,1/75,44/3769,0.022727272727272728,1.142121212121212,0.13510136462452357,0.5891506134762864,0.7054554271398898,0.5860397858459399,ANGPTL4,1
R-HSA-9841922,MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,1/75,44/3769,0.022727272727272728,1.142121212121212,0.13510136462452357,0.5891506134762864,0.7054554271398898,0.5860397858459399,ANGPTL4,1
R-HSA-9851695,Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes,1/75,44/3769,0.022727272727272728,1.142121212121212,0.13510136462452357,0.5891506134762864,0.7054554271398898,0.5860397858459399,ANGPTL4,1
R-HSA-5619115,Disorders of transmembrane transporters,1/75,45/3769,0.022222222222222223,1.1167407407407408,0.11224357704507476,0.5974227487754218,0.708631646213904,0.5886783519045803,CP,1
R-HSA-5693532,DNA Double-Strand Break Repair,1/75,45/3769,0.022222222222222223,1.1167407407407408,0.11224357704507476,0.5974227487754218,0.708631646213904,0.5886783519045803,CDK2,1
R-HSA-5673001,RAF/MAP kinase cascade,2/75,100/3769,0.02,1.0050666666666666,0.007316209121400845,0.5975488476182109,0.708631646213904,0.5886783519045803,VWF/ITGB3,2
R-HSA-69481,G2/M Checkpoints,1/75,46/3769,0.021739130434782608,1.0924637681159421,0.08989625896205902,0.6055305075943915,0.713523209585748,0.5927418981480468,CDK2,1
R-HSA-8856825,Cargo recognition for clathrin-mediated endocytosis,1/75,46/3769,0.021739130434782608,1.0924637681159421,0.08989625896205902,0.6055305075943915,0.713523209585748,0.5927418981480468,IL7R,1
R-HSA-2672351,Stimuli-sensing channels,1/75,47/3769,0.02127659574468085,1.0692198581560284,0.06803448204313255,0.6134771130014345,0.7183118095269961,0.5967199100480309,MLKL,1
R-HSA-9820448,Developmental Cell Lineages of the Exocrine Pancreas,1/75,47/3769,0.02127659574468085,1.0692198581560284,0.06803448204313255,0.6134771130014345,0.7183118095269961,0.5967199100480309,ANXA2,1
R-HSA-1474290,Collagen formation,1/75,48/3769,0.020833333333333332,1.0469444444444445,0.04663506868405551,0.6212657257163435,0.7205903401725615,0.598612743471943,COL4A1,1
R-HSA-69306,DNA Replication,1/75,48/3769,0.020833333333333332,1.0469444444444445,0.04663506868405551,0.6212657257163435,0.7205903401725615,0.598612743471943,CDK2,1
R-HSA-9917777,Epigenetic regulation by WDR5-containing histone modifying complexes,1/75,48/3769,0.020833333333333332,1.0469444444444445,0.04663506868405551,0.6212657257163435,0.7205903401725615,0.598612743471943,ANGPTL4,1
R-HSA-1280218,Adaptive Immune System,5/75,268/3769,0.018656716417910446,0.9375621890547262,-0.15109727890040445,0.6260426551280128,0.7238618199917648,0.6013304450571703,CLEC2B/PTPN22/SOCS3/IFITM1/HLA-DRB5,5
R-HSA-2132295,MHC class II antigen presentation,1/75,49/3769,0.02040816326530612,1.0255782312925168,0.025676434334115834,0.6288994453001315,0.7248996721527995,0.6021926152734496,HLA-DRB5,1
R-HSA-9609646,HCMV Infection,1/75,50/3769,0.02,1.0050666666666666,0.005138446976551265,0.636381311322306,0.7312456061778051,0.6074643442501255,CEBPD,1
R-HSA-2262752,Cellular responses to stress,4/75,218/3769,0.01834862385321101,0.922079510703364,-0.1688659994840712,0.6390915500922136,0.7319860356406727,0.60807943785797,CCL2/CDK2/CDKN1A/IL6,4
R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,1/75,51/3769,0.0196078431372549,0.985359477124183,-0.01499769840878449,0.6437143045061801,0.7319860356406727,0.60807943785797,HIC1,1
R-HSA-68877,Mitotic Prometaphase,1/75,51/3769,0.0196078431372549,0.985359477124183,-0.01499769840878449,0.6437143045061801,0.7319860356406727,0.60807943785797,PLK4,1
R-HSA-397014,Muscle contraction,2/75,109/3769,0.01834862385321101,0.922079510703364,-0.11761480976864215,0.6449390476185386,0.7319860356406727,0.60807943785797,KCNE4/ANXA2,2
R-HSA-2990846,SUMOylation,1/75,52/3769,0.019230769230769232,0.9664102564102566,-0.03474959226095709,0.6509013478526127,0.7364938798332314,0.6118242188088296,HIC1,1
R-HSA-373080,Class B/2 (Secretin family receptors),1/75,54/3769,0.018518518518518517,0.9306172839506172,-0.07316550942141259,0.6648489950190468,0.7477025171946727,0.6211355192627154,ADM,1
R-HSA-5617833,Cilium Assembly,1/75,54/3769,0.018518518518518517,0.9306172839506172,-0.07316550942141259,0.6648489950190468,0.7477025171946727,0.6211355192627154,PLK4,1
R-HSA-109581,Apoptosis,1/75,56/3769,0.017857142857142856,0.8973809523809524,-0.11022932598473409,0.6782465237613522,0.7541408232788577,0.6264839840609572,TNFRSF10B,1
R-HSA-1474165,Reproduction,1/75,56/3769,0.017857142857142856,0.8973809523809524,-0.11022932598473409,0.6782465237613522,0.7541408232788577,0.6264839840609572,CDK2,1
R-HSA-3858494,Beta-catenin independent WNT signaling,1/75,56/3769,0.017857142857142856,0.8973809523809524,-0.11022932598473409,0.6782465237613522,0.7541408232788577,0.6264839840609572,RAC2,1
R-HSA-9006925,Intracellular signaling by second messengers,2/75,116/3769,0.017241379310344827,0.86643678160919535,-0.20817504497031514,0.6787267409509719,0.7541408232788577,0.6264839840609572,CDKN1A/RAC2,2
R-HSA-1640170,Cell Cycle,3/75,174/3769,0.017241379310344827,0.86643678160919535,-0.25700980104186033,0.6813724274762802,0.7548137669647416,0.627043015515518,CDK2/CDKN1A/PLK4,3
R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",1/75,57/3769,0.017543859649122806,0.8816374269005847,-0.12828783471892283,0.6847457186759492,0.7562863161495559,0.6282662996178389,RAC2,1
R-HSA-425393,Transport of inorganic cations/anions and amino acids/oligopeptides,1/75,58/3769,0.017241379310344827,0.86643678160919535,-0.14604713042277245,0.6911153498988221,0.7610496412576315,0.6322233150703511,SLC4A5,1
R-HSA-8978868,Fatty acid metabolism,1/75,60/3769,0.016666666666666666,0.8375555555555555,-0.18071312868937944,0.7034760665250134,0.7723624469265725,0.6416211507896422,ACSL5,1
R-HSA-199418,Negative regulation of the PI3K/AKT network,1/75,61/3769,0.01639344262295082,0.823825136612022,-0.19764081285191917,0.7094721018473709,0.7743500816623222,0.6432723295743901,RAC2,1
R-HSA-8856828,Clathrin-mediated endocytosis,1/75,61/3769,0.01639344262295082,0.823825136612022,-0.19764081285191917,0.7094721018473709,0.7743500816623222,0.6432723295743901,IL7R,1
R-HSA-9006931,Signaling by Nuclear Receptors,2/75,126/3769,0.015873015873015872,0.7976719576719576,-0.32911630578340717,0.7224772065382725,0.786225195350473,0.6531372888828967,PDK1/S1PR3,2
R-HSA-373760,L1CAM interactions,1/75,64/3769,0.015625,0.7852083333333333,-0.24691697170004612,0.7267516159279543,0.7862517482261495,0.6531593470328184,ITGB3,1
R-HSA-9734767,Developmental Cell Lineages,1/75,64/3769,0.015625,0.7852083333333333,-0.24691697170004612,0.7267516159279543,0.7862517482261495,0.6531593470328184,ANXA2,1
R-HSA-73894,DNA Repair,1/75,66/3769,0.015151515151515152,0.7614141414141414,-0.2785976466936125,0.7377037961335335,0.7957737742548321,0.6610695365075704,CDK2,1
R-HSA-212165,Epigenetic regulation of gene expression,1/75,70/3769,0.014285714285714285,0.7179047619047619,-0.33942219891457387,0.7583250072537137,0.8156402694298663,0.6775731398962191,ANGPTL4,1
R-HSA-8953854,Metabolism of RNA,1/75,74/3769,0.013513513513513514,0.6790990990990992,-0.39720728769700275,0.7773449463759249,0.8312648270493994,0.6905528577480076,ZFP36,1
R-HSA-983168,Antigen processing: Ubiquitination & Proteasome degradation,1/75,74/3769,0.013513513513513514,0.6790990990990992,-0.39720728769700275,0.7773449463759249,0.8312648270493994,0.6905528577480076,SOCS3,1
R-HSA-1266738,Developmental Biology,9/75,551/3769,0.016333938294010888,0.8208348457350272,-0.6484462164619096,0.7884011573243958,0.8406582945533904,0.6983562503829019,EDN1/FOXF1/CDK2/CDKN1A/ANGPTL4/ANXA2/COL4A1/CEBPD/ITGB3,9
R-HSA-418555,G alpha (s) signalling events,1/75,78/3769,0.01282051282051282,0.6442735042735043,-0.45230264358026145,0.794886404347963,0.845137843703294,0.702077525921371,ADM,1
R-HSA-5576891,Cardiac conduction,1/75,80/3769,0.0125,0.6281666666666668,-0.4789350474866677,0.8031385135756041,0.8514648997792937,0.7073335725051316,KCNE4,1
R-HSA-1852241,Organelle biogenesis and maintenance,1/75,81/3769,0.012345679012345678,0.6204115226337448,-0.4920369379641466,0.8071408479431372,0.8532631821113165,0.7088274514267553,PLK4,1
R-HSA-5653656,Vesicle-mediated transport,3/75,216/3769,0.013888888888888888,0.697962962962963,-0.6513690307549821,0.8137119366835566,0.8565775242938556,0.71158075986858,IL7R/COL4A1/GJA4,3
R-HSA-211859,Biological oxidations,1/75,83/3769,0.012048192771084338,0.6054618473895582,-0.5178309698290033,0.8149061852741546,0.8565775242938556,0.71158075986858,CYP3A43,1
R-HSA-983712,Ion channel transport,1/75,87/3769,0.011494252873563218,0.5776245210727969,-0.5678767192513738,0.8295229804527273,0.8694716792280712,0.7222922626873309,MLKL,1
R-HSA-68886,M Phase,1/75,93/3769,0.010752688172043012,0.5403584229390681,-0.6394559933744166,0.8493381944464731,0.8852257237892818,0.7353795486386069,PLK4,1
R-HSA-8939211,ESR-mediated signaling,1/75,93/3769,0.010752688172043012,0.5403584229390681,-0.6394559933744166,0.8493381944464731,0.8852257237892818,0.7353795486386069,S1PR3,1
R-HSA-983169,Class I MHC mediated antigen processing & presentation,1/75,98/3769,0.01020408163265306,0.5127891156462584,-0.6962664368154564,0.8641008831593383,0.8980823785644808,0.7460598991204223,SOCS3,1
R-HSA-5663205,Infectious disease,4/75,322/3769,0.012422360248447204,0.6242650103519668,-1.0044459388839009,0.8947248040181444,0.9273058192905138,0.7703365554276815,IL1R1/IL1B/IL6/CEBPD,4
R-HSA-195258,RHO GTPase Effectors,1/75,118/3769,0.00847457627118644,0.4258757062146893,-0.9027731721367772,0.9101636469546814,0.9404760426378507,0.7812773953065504,RAC2,1
R-HSA-199991,Membrane Trafficking,2/75,200/3769,0.01,0.5025333333333333,-1.0300145099396665,0.9149894515187684,0.9404760426378507,0.7812773953065504,IL7R/GJA4,2
R-HSA-556833,Metabolism of lipids,3/75,271/3769,0.01107011070110701,0.556309963099631,-1.0801698544967844,0.9150577712152062,0.9404760426378507,0.7812773953065504,HILPDA/ANGPTL4/ACSL5,3
R-HSA-9679506,SARS-CoV Infections,1/75,123/3769,0.008130081300813009,0.4085636856368564,-0.9501449043905065,0.9190241472354431,0.9419361065848032,0.7824903076038765,IL1R1,1
R-HSA-195721,Signaling by WNT,1/75,130/3769,0.007692307692307693,0.38656410256410256,-1.0141156112518723,0.9299972289121697,0.9505496538605049,0.7896458006465646,RAC2,1
R-HSA-9709957,Sensory Perception,1/75,138/3769,0.007246376811594203,0.3641545893719807,-1.0842154532415966,0.9407497848490366,0.9588909652731228,0.7965751404260366,CHRNA10,1
R-HSA-9824446,Viral Infection Pathways,2/75,229/3769,0.008733624454148471,0.43889374090247446,-1.24824218761722,0.9484515221172264,0.964085338415862,0.8008902384564203,IL1R1/CEBPD,2
R-HSA-422475,Axon guidance,2/75,234/3769,0.008547008547008548,0.42951566951566955,-1.2837917278771616,0.9527902064450657,0.9658421270812996,0.802349647532687,COL4A1/ITGB3,2
R-HSA-9675108,Nervous system development,2/75,249/3769,0.008032128514056224,0.4036412315930388,-1.3873102153663772,0.9638343500586437,0.974368058802454,0.809432356103319,COL4A1/ITGB3,2
R-HSA-9012999,RHO GTPase cycle,1/75,197/3769,0.005076142131979695,0.255093062605753,-1.53009022300937,0.9828793226489461,0.9909137585289102,0.8231772901577293,RAC2,1
R-HSA-194315,Signaling by Rho GTPases,1/75,282/3769,0.0035460992907801418,0.1782033096926714,-2.044092767237183,0.9972412252465037,0.9996681960304288,0.8304498242983933,RAC2,1
R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",1/75,287/3769,0.003484320557491289,0.17509872241579558,-2.071410505002867,0.9975255754390138,0.9996681960304288,0.8304498242983933,RAC2,1
R-HSA-1430728,Metabolism,5/75,747/3769,0.006693440428380187,0.336367692994199,-2.885879707220094,0.9996681960304288,0.9996681960304288,0.8304498242983933,CYP3A43/HILPDA/PDK1/ANGPTL4/ACSL5,5
